Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, describes the history and current use of stereotactic radiation therapy for inoperable lung lesions.Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, describes the history and current use of stereotactic radiation therapy for inoperable lung lesions.

This is the first video in our series from a program filmed directly from ASCO 2013. Drs. Nate Pennell, Mary Pinder, and Jack West discuss the Biomarkers France trial of testing on a national scale for clinically relevant biomarkers in advanced non-small cell lung cancer (NSCLC).

[powerpress]

>> Discuss this GRACEcast Video in the GRACE Discussion Forums

Dr. Heather Wakelee from Stanford University discusses the open question of whether patients with resectable or locally advanced NSCLC should have testing for molecular markers, as well as how we might use this information in clinical practice.

 [powerpress]

Dr. Greg Riely from Memorial Sloan-Kettering reviews strategies for managing acquired resistance to EGFR inhibitors and other targeted therapies in advanced non-small cell lung cancer.

[powerpress]

Dr. Lecia Sequist describes the state of the art and her view of current best practices on molecular testing for advanced non-small cell lung cancer.

[powerpress]

Dr. Geoffrey Oxnard describes the new finding of individuals with an inherited T790M mutation in the EGFR gene, the unclear significance of it, and a study being conducted to learn more about it.

[powerpress]

Here's a brief video that explains my approach to a so-called "mixed response" to treatment for a lung cancer.  

[powerpress]

There isn't a formal teaching or "best answer" about how to approach this issue, but what I explain here is a common and I think very sensible strategy for a still controversial clinical setting (if I do say so myself).  I'd welcome your comments.

I hope you find it helpful if you or someone you care about faces this situation.

Here's a brief video I did for Swedish Cancer Institute that explains the basic concepts of maintenance therapy for advanced NSCLC.

I hope it's helpful to those of you just learning about what might come after first line therapy for advanced NSCLC.

I'm happy to bring you now the second part of the Santa Monica webinar, developed with the LUNGevity Foundation, on "Molecular Markers in Advanced NSCLC: Who to Test and What to Test For?", in which I was joined by Drs.

Here's the final piece of the webinar with our own Dr. Jared Weiss on Highlights in Lung Cancer from 2011 -- the question and answer session that followed his presentation.  Below is the transcript, figures, and the audio and video versions of the podcast.